This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

I. Reduction in Incidence of Coronary Heart Disease

Lipid Research Clinics Program

JAMA. 1984;251(3):351-364.

Abstract
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (P<.05) of the primary end point—definite CHD death and/or definite nonfatal myocardial infarction—reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.

(JAMA 1984;251:351-364)

Author Affiliations
From the Lipid Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute, Bethesda, Md.

Footnotes
Reprint requests to Lipid Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute, Federal 401, Bethesda, MD 20205 (Basil M. Rifkind, MD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration
Staels and Fonseca
Diabetes Care 2009;32:S237-S245.
FULL TEXT  

Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
Xu and Zou
Circulation 2009;120:1266-1286.
FULL TEXT  

The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Meaney et al.
J Clin Pharmacol 2009;49:838-847.
ABSTRACT | FULL TEXT  

Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease
Stein
Mayo Clin Proc. 2009;84:307-309.
FULL TEXT  

History of the cholesterol controversy in Britain
Thompson
QJM 2009;102:81-86.
ABSTRACT | FULL TEXT  

Response to Letter of Mascitelli L, Ravnskov U, Pezzetta F, and Goldstein M
Whayne
ANGIOLOGY 2009;60:129-130.
 

Acute Coronary Syndromes
Hollenberg
ACCP Crit Care Med Brd Rev 2009;20:129-144.
FULL TEXT  

Is There a Problem With Ezetimibe or Just ENHANCEd Hype?
Whayne
ANGIOLOGY 2009;59:661-663.
 

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart et al.
Diabetes and Vascular Disease Research 2008;5:319-335.
ABSTRACT  

American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden
Diabetes Care 2008;31:2222-2229.
FULL TEXT  

Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin: Glucose and Lipid Effects
Bays et al.
Arch Intern Med 2008;168:1975-1983.
ABSTRACT | FULL TEXT  

The Statins in Preventive Cardiology
Steinberg
NEJM 2008;359:1426-1427.
FULL TEXT  

Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy
Goldberg et al.
Arch Intern Med 2008;168:1531-1540.
ABSTRACT | FULL TEXT  

Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages
Sehayek and Hazen
Arterioscler. Thromb. Vasc. Bio. 2008;28:1296-1297.
ABSTRACT | FULL TEXT  

Preventing Heart Disease in the 21st Century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study
McGill et al.
Circulation 2008;117:1216-1227.
FULL TEXT  

State of the Art Reviews: The Oatmeal-Cholesterol Connection: 10 Years Later
Andon and Anderson
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:51-57.
ABSTRACT  

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT  

Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter and Rye
Arterioscler. Thromb. Vasc. Bio. 2008;28:39-46.
ABSTRACT | FULL TEXT  

Human cholesterol metabolism and therapeutic molecules
Charlton-Menys and Durrington
Exp Physiol 2008;93:27-42.
ABSTRACT | FULL TEXT  

State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health
O'Neil and Nicklas
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:457-481.
ABSTRACT  

HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
Barter et al.
NEJM 2007;357:1301-1310.
ABSTRACT | FULL TEXT  

Could targeted food taxes improve health?
Mytton et al.
J. Epidemiol. Community Health 2007;61:689-694.
ABSTRACT | FULL TEXT  

The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease
Rippe et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:10-19.
ABSTRACT  

Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?
Milani and Lavie
J Am Coll Cardiol 2006;48:1791-1792.
FULL TEXT  

THE GREAT DEBATE EDITORIAL, REVISITED: RESPONSE
Freedland et al.
Psychosom. Med. 2006;68:638-640.
FULL TEXT  

Profiling risk: the emergence of coronary heart disease epidemiology in the United States (1947-70)
Oppenheimer
Int J Epidemiol 2006;35:720-730.
ABSTRACT | FULL TEXT  

Role of the Pharmacist in the Management of Dyslipidemia
Olson and Potts
Journal of Pharmacy Practice 2006;19:94-102.
ABSTRACT  

Association between Carbohydrate Intake and Serum Lipids.
Ma et al.
J. Am. Coll. Nutr. 2006;25:155-163.
ABSTRACT | FULL TEXT  

Oxidative Stress and Vascular Disease: 2005 Duff Lecture
Heistad
Arterioscler. Thromb. Vasc. Bio. 2006;26:689-695.
ABSTRACT | FULL TEXT  

Statins, cholesterol, and the prevention of coronary heart disease
Freeman
FASEB J. 2006;20:200-201.
FULL TEXT  

Associations of Changes in Exercise Level With Subsequent Disability Among Seniors: A 16-Year Longitudinal Study
Berk et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2006;61:97-102.
ABSTRACT | FULL TEXT  

Stimulation of Liver-Directed Cholesterol Flux in Mice by Novel N-Acetylgalactosamine-Terminated Glycolipids With High Affinity for the Asialoglycoprotein Receptor
Rensen et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:169-175.
ABSTRACT | FULL TEXT  

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT  

Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT | FULL TEXT  

Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture
Gotto
J Am Coll Cardiol 2005;46:1219-1224.
FULL TEXT  

The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:2020-2030.
ABSTRACT | FULL TEXT  

Evaluation of Macrocirculatory Endothelium-Dependent and Endothelium-Independent Vasoreactivity in Vascular Disease
Abularrage et al.
PERSPECT VASC SURG ENDOVASC THER 2005;17:245-253.
ABSTRACT  

Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Eddy et al.
ANN INTERN MED 2005;143:251-264.
ABSTRACT | FULL TEXT  

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events
Whitney et al.
ANN INTERN MED 2005;142:95-104.
ABSTRACT | FULL TEXT  

Pathogenesis of Atherosclerosis
Crowther
ASH Education Book 2005;2005:436-441.
ABSTRACT | FULL TEXT  

Serum Lipid Concentrations and Prevalence of Dyslipidemia in a Large Professional Population in Beijing
Li et al.
Clin. Chem. 2005;51:144-150.
ABSTRACT | FULL TEXT  

Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years
Rifai et al.
Clin. Chem. 2004;50:1861-1870.
FULL TEXT  

Quality of Life After Coronary Artery Bypass Graft: Results From the POST CABG Trial
Fox et al.
Chest 2004;126:487-495.
ABSTRACT | FULL TEXT  

Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers
Kluft
Eur Heart J Suppl 2004;6:C21-C27.
ABSTRACT | FULL TEXT  

What does the future hold for the patient with peripheral arterial disease?
Sillesen
Eur Heart J Suppl 2004;6:C43-C48.
ABSTRACT | FULL TEXT  

The Clinician as Investigator: Participating in Clinical Trials in the Practice Setting
Lader et al.
Circulation 2004;109:2672-2679.
ABSTRACT | FULL TEXT  

Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK
Greene and Durrington
JRSM 2004;97:226-229.
ABSTRACT | FULL TEXT  

Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy
DANESH and KANWAR
FASEB J. 2004;18:805-815.
ABSTRACT | FULL TEXT  

A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study
Fisac et al.
J. Clin. Endocrinol. Metab. 2003;88:5186-5192.
ABSTRACT | FULL TEXT  

Validation of the Archimedes Diabetes Model
Eddy and Schlessinger
Diabetes Care 2003;26:3102-3110.
ABSTRACT | FULL TEXT  

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
Chandler et al.
J. Lipid Res. 2003;44:1887-1901.
ABSTRACT | FULL TEXT  

Lipid-Lowering Drugs and the Risk of Depression and Suicidal Behavior
Yang et al.
Arch Intern Med 2003;163:1926-1932.
ABSTRACT | FULL TEXT  

An In Vitro Study of the Probiotic Potential of a Bile-Salt-Hydrolyzing Lactobacillus fermentum Strain, and Determination of Its Cholesterol-Lowering Properties
Pereira et al.
Appl. Environ. Microbiol. 2003;69:4743-4752.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels
Katan et al.
Mayo Clin Proc. 2003;78:965-978.
ABSTRACT  

Ezetimibe for Management of Hypercholesterolemia
Mauro and Tuckerman
The Annals of Pharmacotherapy 2003;37:839-848.
ABSTRACT | FULL TEXT  

DAIS: how it relates to other lipid intervention studies in diabetes
Steiner
British Journal of Diabetes & Vascular Disease 2003;3:212-215.
ABSTRACT  

Donald Sharp Fredrickson, MD: 1924-2002
Gotto
Circulation 2003;107:1714-1716.
FULL TEXT  

Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL
Matthan et al.
J. Lipid Res. 2003;44:800-806.
ABSTRACT | FULL TEXT  

Differential Effects of Lipid-Lowering Therapies on Stroke Prevention: A Meta-analysis of Randomized Trials
Corvol et al.
Arch Intern Med 2003;163:669-676.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Risk of Cardiovascular Disease: Implications of the Results of the Women's Health Initiative
Kuller
Arterioscler. Thromb. Vasc. Bio. 2003;23:11-16.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Statins and stroke: evidence for cholesterol-independent effects
Di Napoli et al.
Eur Heart J 2002;23:1908-1921.
 

Postponed Development of Disability in Elderly Runners: A 13-Year Longitudinal Study
Wang et al.
Arch Intern Med 2002;162:2285-2294.
ABSTRACT | FULL TEXT  

Inhibition of the Apical Sodium-Dependent Bile Acid Transporter Reduces LDL Cholesterol and ApoB by Enhanced Plasma Clearance of LDL ApoB
Huff et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:1884-1891.
ABSTRACT | FULL TEXT  

Dose Response of Almonds on Coronary Heart Disease Risk Factors: Blood Lipids, Oxidized Low-Density Lipoproteins, Lipoprotein(a), Homocysteine, and Pulmonary Nitric Oxide: A Randomized, Controlled, Crossover Trial
Jenkins et al.
Circulation 2002;106:1327-1332.
ABSTRACT | FULL TEXT  

Donald S. Fredrickson, MD: 1924-2002
Gotto
Arterioscler. Thromb. Vasc. Bio. 2002;22:1506-1508.
FULL TEXT  

Hypertensive retinopathy and incident coronary heart disease in high risk men
Duncan et al.
Br J Ophthalmol 2002;86:1002-1006.
ABSTRACT | FULL TEXT  

Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study
McKeown et al.
Am. J. Clin. Nutr. 2002;76:390-398.
ABSTRACT | FULL TEXT  

Primary Prevention Drug Therapy: Can It Meet Patients' Requirements for Reduced Risk?
Llewellyn-Thomas et al.
Med Decis Making 2002;22:326-339.
ABSTRACT  

Coronary plaque regression: role of low density lipoprotein-apheresis
Barter
J Am Coll Cardiol 2002;40:228-230.
FULL TEXT  

Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels
Blake et al.
J Am Coll Cardiol 2002;40:49-55.
ABSTRACT | FULL TEXT  

Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events?
Aronow
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:M411-413.
FULL TEXT  

Reducing cholesterol and atherosclerosis
Hornung
QJM 2002;95:339-341.
FULL TEXT  

Disparities in the Diagnosis and Pharmacologic Treatment of High Serum Cholesterol by Race and Ethnicity: Data From the Third National Health and Nutrition Examination Survey
Nelson et al.
Arch Intern Med 2002;162:929-935.
ABSTRACT | FULL TEXT  

Lyrical Language and Nursing Discourse: Can Science be the Tool of Love?
Cody
Nurs Sci Q 2002;15:98-106.
ABSTRACT  

Effect of a Rapeseed Oil Substituting Diet on Serum Lipids and Lipoproteins in Children and Adolescents with Familial Hypercholesterolemia
Gulesserian and Widhalm
J. Am. Coll. Nutr. 2002;21:103-108.
ABSTRACT | FULL TEXT  

Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2002;87:423-437.
FULL TEXT  

Methods for Measurement of LDL-Cholesterol: A Critical Assessment of Direct Measurement by Homogeneous Assays versus Calculation
Nauck et al.
Clin. Chem. 2002;48:236-254.
ABSTRACT | FULL TEXT  

How best to combat the enemies? Lipid lowering
Cobbe
Eur Heart J Suppl 2002;4:A48-A52.
ABSTRACT  

Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial
White et al.
Circulation 2001;104:2660-2665.
ABSTRACT | FULL TEXT  

Antioxidant Supplements Block the Response of HDL to Simvastatin-Niacin Therapy in Patients With Coronary Artery Disease and Low HDL
Cheung et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1320-1326.
ABSTRACT | FULL TEXT  

Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet
Maki et al.
Am. J. Clin. Nutr. 2001;74:33-43.
ABSTRACT | FULL TEXT  

Fillers can transform people's lives
Le Fanu
BMJ 2001;322:998a-998.
FULL TEXT  

Primary Prevention of Coronary Heart Disease: Where Do We Go From Here?
Gotto
Arch Intern Med 2001;161:922-924.
FULL TEXT  

Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population: The Framingham Heart Study
Lloyd-Jones et al.
Arch Intern Med 2001;161:949-954.
ABSTRACT | FULL TEXT  

Optimization of {beta}-Quantification Methods for High-Throughput Applications
Cole et al.
Clin. Chem. 2001;47:712-721.
ABSTRACT | FULL TEXT  

Effects of Policosanol in Older Patients With Type II Hypercholesterolemia and High Coronary Risk
Castaño et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2001;56:186M-193.
ABSTRACT | FULL TEXT  

Comparison of the effect of dietary fat restriction with that of energy restriction on human lipid metabolism
Raeini-Sarjaz et al.
Am. J. Clin. Nutr. 2001;73:262-267.
ABSTRACT | FULL TEXT  

The Year in Review: Cardiology
Sanoski
Journal of Pharmacy Practice 2001;14:18-40.
ABSTRACT  

Choose a Diet That Is Low in Saturated Fat and Cholesterol and Moderate in Total Fat: Subtle Changes to a Familiar Message
Dixon and Ernst
J. Nutr. 2001;131:510S-526.
ABSTRACT | FULL TEXT  

Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
Grover et al.
CMAJ 2000;163:1263-1269.
ABSTRACT | FULL TEXT